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From Orphan Drugs to Adopted Therapies: Advancing C3-Targeted Intervention to
the Clinical Stage
Abstract
Complement dysregulation is increasingly recognized as an important pathogenic driver in a number of
clinical disorders. Complement-triggered pathways intertwine with key inflammatory and tissue
destructive processes that can either increase the risk of disease or exacerbate pathology in acute or
chronic conditions. The launch of the first complement-targeted drugs in the clinic has undeniably stirred
the field of complement therapeutic design, providing new insights into complement's contribution to
disease pathogenesis and also helping to leverage a more personalized, comprehensive approach to
patient management. In this regard, a rapidly expanding toolbox of complement therapeutics is being
developed to address unmet clinical needs in several immune-mediated and inflammatory diseases.
Elegant approaches employing both surface-directed and fluid-phase inhibitors have exploited diverse
components of the complement cascade as putative points of therapeutic intervention. Targeting C3, the
central hub of the system, has proven to be a promising strategy for developing biologics as well as smallmolecule inhibitors with clinical potential. Complement modulation at the level of C3 has recently shown
promise in preclinical primate models, opening up new avenues for therapeutic intervention in both acute
and chronic indications fueled by uncontrolled C3 turnover. This review highlights recent developments in
the field of complement therapeutics, focusing on C3-directed inhibitors and alternative pathway (AP)
regulator-based approaches. Translational perspectives and considerations are discussed, particularly
with regard to the structure-guided drug optimization and clinical advancement of a new generation of
C3-targeted peptidic inhibitors.
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Complement dysregulation is increasingly recognized as an important pathogenic driver in a
number of clinical disorders. Complement-triggered pathways intertwine with key inflammatory
and tissue destructive processes that can either increase the risk of disease or exacerbate pathology
in acute or chronic conditions. The launch of the first complement-targeted drugs in the clinic has
undeniably stirred the field of complement therapeutic design, providing new insights into
complement's contribution to disease pathogenesis and also helping to leverage a more
personalized, comprehensive approach to patient management. In this regard, a rapidly expanding
toolbox of complement therapeutics is being developed to address unmet clinical needs in several
immune-mediated and inflammatory diseases. Elegant approaches employing both surfacedirected and fluid-phase inhibitors have exploited diverse components of the complement cascade
as putative points of therapeutic intervention. Targeting C3, the central hub of the system, has
proven to be a promising strategy for developing biologics as well as small-molecule inhibitors
with clinical potential. Complement modulation at the level of C3 has recently shown promise in
preclinical primate models, opening up new avenues for therapeutic intervention in both acute and
chronic indications fueled by uncontrolled C3 turnover. This review highlights recent
developments in the field of complement therapeutics, focusing on C3-directed inhibitors and
alternative pathway (AP) regulator-based approaches. Translational perspectives and
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considerations are discussed, particularly with regard to the structure-guided drug optimization
and clinical advancement of a new generation of C3-targeted peptidic inhibitors.
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Complement dysregulation; C3 convertase; AMY-101; clinical efficacy; primate models; peptidic
C3 inhibitors

Introduction
1. Complement-targeted drug discovery: a changing landscape with emerging
opportunities
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Traditionally perceived as a phylogenetically conserved antimicrobial sentinel with
enhanced pathogen-neutralizing and ‘waste disposal’ capabilities, complement had remained
for several decades behind the curtains of mainstream immunological research. However, the
advent of high-throughput gene profiling and other technological advancements has led to
unprecedented discoveries in preclinical models and large-scale patient cohorts that
implicate complement dysregulation in the pathogenesis of several immune-mediated and
inflammatory diseases (Ricklin and Lambris, 2013a). It is now widely appreciated that
complement plays a multitasking role in tissue immunosurveillance and homeostasis by
extending vital links to diverse immunoregulatory networks (Ricklin et al., 2010;Kolev et al.,
2014). While tightly regulated under steady-state conditions, this innate immune system is
vulnerable to subtle genetic and acquired (e.g. autoimmune-driven) alterations of its activity
that can collectively tilt the balance of tissue immunosurveillance toward a persistent hostdirected attack, with detrimental proinflammatory consequences (Ricklin and Lambris,
2013a). Such regulatory perturbations can skew clinical phenotypes, either by increasing the
risk for a disease or exacerbating the clinical manifestations of a chronic condition.

Author Manuscript

Seminal studies employing genome-wide association studies (GWAS) and next-generation
sequencing have provided important insights into complement's involvement in human
pathophysiology by revealing that subtle functional modifications of key complement
activities (via mutations or common polymorphisms) can unleash a derailed complement
response on host surfaces that culminates in inflammatory tissue damage and chronic
pathology (Schramm et al., 2014;Ricklin and Lambris, 2013a). The predisposing role of
certain complement gene polymorphisms in age-related macular degeneration (AMD) is an
illustrative example of how this complex interplay can influence disease susceptibility
(Schramm et al., 2014). Clearly, complement dysregulation has been recognized as a key
pathogenic driver in certain rare but chronic debilitating diseases, including paroxysmal
nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (Reis et
al., 2015). In fact, therapeutic intervention in these diseases using complement inhibitors has
led to remarkable clinical benefit, restoring complement imbalance and drastically
improving therapeutic outcomes in patients. The expanding spectrum of complementmediated clinical disorders, together with the successful bedside application of the first
complement-specific drugs and the clinical experience gained thus far have vigorously
rekindled the interest of pharmaceutical companies in the development and clinical
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advancement of new complement-targeted drug leads (Morgan and Harris, 2015;Reis et al.,
2015).
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Nevertheless, the path to clinical intervention has remained challenging, particularly in light
of recent findings that argue for a more complex impact of the “complotype” on disease
pathogenesis and therapeutic responses (Harris et al., 2012). For instance, a fair proportion
of PNH patients receiving treatment with first-in-class anti-complement agents (i.e.,
eculizumab) have shown an insufficient response to this standard anti-C5 therapy (Risitano,
2013;Nishimura et al., 2014). These unmet clinical needs have shed light on previously
elusive pathogenetic mechanisms that should guide alternative therapeutic interventions. C3
opsonin-mediated extravascular hemolysis in PNH patients under eculizumab treatment is an
emerging clinical observation that calls for the evaluation of new treatment options
(Mastellos et al., 2014). Therapy-modifying effects have also been ascribed to genetic
alterations affecting complement genes (e.g., C5 and CR1) in certain PNH patients (Rondelli
et al., 2014;Nishimura et al., 2014). The growing appreciation that a fraction of patients are
refractory to standard therapeutic regimens because of genetic variance, pharmacologic
breakthrough phenomena, or ongoing opsonization has prompted the design of new
complement-targeted therapeutic modalities (e.g., C3 therapeutics) that can effectively
circumvent these limitations, consolidating potential variations in patient responses. Of note,
the emerging recognition of complement's involvement in conditions that still remain orphan
despite the availability of options in the clinic (e.g., C3 glomerulopathy) further underscores
the need for alternative therapeutic strategies.

Author Manuscript

Overall, genomic and epidemiological studies and clinical follow-up observations in patients
undergoing complement intervention have reshaped our choice of overarching tenets to
guide complement therapeutic design in the future. Whatever the favored approach or target
protein, the ultimate goal should be to design a more comprehensive therapeutic protocol
targeting the desired complement activity in the clinic (i.e., through a more personalized
medical approach). While acknowledging the remarkable versatility and ingenuity of the
various “schools” of complement therapeutic design, we have focused this review on
emerging trends and opportunities regarding the translational potential of next-generation
C3-targeted therapeutics.
2. Current trends in complement-targeted therapeutic intervention

Author Manuscript

Complement offers ample opportunity for targeted therapeutic modulation, at various steps
of the cascade and in a disease-specific context. Although only two complement-targeted
drugs have thus far entered the clinic, the therapeutic anti-C5 antibody eculizumab (Soliris;
Alexion Pharmaceuticals) and various preparations of the physiological regulator C1
esterase inhibitor (C1-INH), several new candidate drugs targeting various components of
the cascade are currently in different stages of clinical development (Ricklin and Lambris,
2013b;Morgan and Harris, 2015;Reis et al., 2015). In terms of strict complement specificity,
it should be emphasized that while C1-INH effectively blocks complement activation via the
classical or lectin pathways, it also exerts broader modulation over various blood-borne
proteolytic cascades, including the coagulation and kallikrein/bradykinin pathways.
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Therefore its therapeutic impact in complement-driven pathologies has to be considered
under a broader inhibitory scope.
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Being an intricate protein-protein interaction network that is finely regulated by fluid-phase
and surface-bound regulators, complement taps into several immunoregulatory and
proinflammatory pathways recruiting numerous pattern-recognition molecules, protein
assemblies, cofactors, and receptors (Ricklin et al., 2010). Complement activation can
proceed via any of three canonical pathways (alternative, lectin, classical) that converge at
the cleavage of the third complement component (C3) through sequential proteolytic steps
(Figure 1). Large multi-protein enzymatic complexes, termed convertases, are responsible
for the proteolytic activation of the central components C3 and C5 and the subsequent
release of their respective bioactive fragments: C3a and C3b, C5a and C5b, respectively.
Regardless of the initial route of activation, amplification of C3b deposition via the
alternative pathway (AP) may lead to high opsonic turnover on target surfaces and thus has
been implicated as a key pathogenic mechanism underlying several diseases. In fact, APmediated amplification of complement responses has been shown to account for more than
80% of the downstream activation that is elicited following initial triggering of the CP or LP
in certain pathophysiological settings (Harboe et al., 2004; Harboe et al., 2009). C5b forms
the initial component of the terminal (lytic) pathway, promoting a multi-protein assemblage
that leads to the formation of the cell-perforating membrane attack complex (MAC, C5b-9)
(Ricklin and Lambris, 2013a). The direct convertase-independent cleavage of C3 and C5,
mainly by extrinsic proteases of the coagulation and fibrinolytic systems, has also been
reported under certain pathophysiological circumstances (Huber-Lang et al., 2006).

Author Manuscript

Blockade of a specific initiation route (AP, lectin, or classical) offers a targeted therapeutic
approach that blunts upstream complement activation while sparing the immunomodulatory
and homeostatic functions of downstream complement effectors/pathways. However, this
approach might have only minimal therapeutic merit if multiple initiation routes converge in
triggering pathological sequelae in the clinical condition in question. There are, however,
disorders that might benefit from targeting a single pathway, including autoimmune
hemolytic anemias, since complement-mediated hemolysis in these conditions is mainly
triggered by the classical pathway (CP) via binding of autoreactive IgGs and IgMs to
circulating erythrocytes (Berentsen, 2015). Although preclinical evidence from animal
models points to a distinct role of the LP in triggering pathology in certain diseases, the
clinical impact of specifically targeting LP activation still needs to be further explored.

Author Manuscript

From a different standpoint, strategies targeting the central protein, C3, offer a broader and
more comprehensive interception by blunting amplification and downstream receptortriggered effector mechanisms, as exemplified by compstatin-based C3 inhibitors and
engineered versions of natural C3 regulators (Ricklin and Lambris, 2016b). Such a broadly
inhibiting approach may have greater therapeutic leverage in clinical conditions associated
with systemic complement activation. In general, any complement-targeted therapeutic
protocol will require a thorough consideration of potential prophylactic measures that can
compensate for a likely compromised response in terms of microbial immune surveillance,
particularly in chronic interventions (Ricklin and Lambris, 2016a).
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Targeting the terminal pathway may prove rewarding in clinical conditions that are largely
driven by terminal pathway effectors such as C5a and the MAC. Blockade of the terminal
pathway via C5 targeting abrogates the detrimental proinflammatory consequences of the
C5a-C5aR axis and simultaneously affords protection from the cytolytic effects of the MAC
on autologous surfaces, while also preserving upstream homeostatic responses driven by C3
activation and AP amplification. Alternatively, specific interception of C5aR1 signaling
(e.g., using small-molecule antagonists) appears to be a more tailored approach for
conditions largely fueled by C5a-mediated inflammatory activation, because this approach
preserves the bactericidal activity of complement (in serum) elicited by MAC assembly on
complement-sensitive microbial surfaces (Sprong et al., 2003;Ricklin and Lambris, 2013c).
Given that C5a can trigger divergent cellular responses by binding to two receptors (i.e.,
C5aR1/CD88 and C5aR2/C5L2) with distinct and perhaps even opposing functions,
therapeutic targeting of C5a (e.g. via antibody-based blockade) should be distinguished from
the pharmacological antagonism of any of the two C5a receptors. Selection of the optimal
target or pathway for intervention inextricably depends on its disease-specific contribution
and the underlying mechanisms driving pathology in that particular clinical condition.
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Fortunately, the complement drug discovery field has witnessed a surge in the development
of diversified and mechanistically subtle approaches for inhibiting complement at various
steps of the cascade. Potent and highly selective inhibitors have been registered in the
pipeline of pharmaceutical companies in an all-inclusive scope ranging from small-sized
molecules to larger biologics (Morgan and Harris, 2015). Since most of the activities of
complement rely on protein-protein interactions (PPI), the development of biologics (e.g.,
therapeutic antibodies) has gained considerable traction for blocking larger contacts and
interfaces (exosites) uniquely involved in substrate recognition and binding. An illustrative
example of the Ab-based approach is a humanized anti-FD Fab (lampalizumab, Genentech/
Roche) that specifically targets the FD exosite to prevent activation of the AP C3 proconvertase (C3bB) (Katschke, Jr. et al., 2012). This antibody blocks AP activation and has
shown clinical potential for the treatment of geographic atrophy (GA), an advanced dry form
of age-related macular degeneration (AMD) (Regillo C.D. et al., 2013), after local
administration. Other elegant approaches exploiting biologics as potential PPI inhibitors
include recombinant fusion proteins encompassing regulatory (CCP) modules of natural
regulators (e.g., TT30, miniFH) (Fridkis-Hareli et al., 2011;Schmidt et al., 2013), parasitesecreted immune evasion proteins (e.g., OmCI; (Roversi et al., 2007), recombinant protein
scaffolds (e.g. SOBI002) (Swedish Orphan Biovitrum, 2016), and oligonucleotide-based
ligands such as aptamers (e.g., Zimura), liver-targeted RNAi therapeutics (ALN-CC5,
Alnylam), or Spiegelmers (e.g., NOX-D21) (Ricklin and Lambris, 2016b). The development
of highly potent peptidic inhibitors has defined a unique class of small-sized complement
therapeutics that have shown great promise for clinical translation in various indications.
This approach has yielded specific C5aR1 antagonists (e.g., PMX53) (Woodruff et al.,
2011), potent C3-targeted peptide inhibitors of the compstatin family (e.g., the Cp40-based
therapeutic AMY-101, Amyndas Pharmaceuticals)(Mastellos et al., 2015), FH-binding
peptides with promising results in models of biomaterial-triggered thromboinflammation
(Wu et al., 2011) (Ricklin and Lambris, 2016a), and a peptide-based C5 inhibitor (Ra
Pharmaceuticals) (Ra Pharmaceuticals, 2016). As compared to larger biologics, these
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peptide-based therapeutics are expected to offer advantages regarding lowered production
costs and better tissue distribution; however, their clinical efficacy will need to be closely
monitored during clinical development.
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Complement interception: systemic vs. locally targeted—Complement-based
therapeutic design has been directly influenced by concepts and approaches originating from
two intersecting schools of thought: i) the “systemic interception” approach, which targets
complement proteins in the fluid phase using biologics or small-sized inhibitors, and ii) the
“surface-targeting” approach, which directs natural or engineered chimeric inhibitors closer
to the complement-opsonized surface [reviewed in (Ricklin and Lambris, 2013c)]. In general
terms, systemic approaches may better apply to conditions in which complement
dysregulation impacts multiple physiological systems, leading to adverse systemic
inflammatory responses that propagate to vital target organs. In contrast, targeting
complement inhibitors to the diseased or incompatible xenogeneic surface is considered
advantageous when the pathological ramifications are mainly driven by a local complement
imbalance (e.g., a lack of surface-bound C3 regulators), rendering a host surface prone to
uncontrollable complement attack. This surface-targeted approach may also be beneficial in
conditions in which persistent C3 opsonic turnover fuels a vicious cycle of inflammation on
malignantly transformed surfaces (e.g., tumor cells), transplants, or biomaterials (Ekdahl et
al., 2011). Indeed, promising examples of this surface-directed therapeutic approach include
fusion proteins (e.g., TT30 [FH-CR2]), condensed versions of AP regulators with enhanced
surface recognition and inhibitory potency (e.g., mini-FH), and targeting moieties that
recruit soluble regulators to biomaterial surfaces, thereby attenuating AP activation and C3
opsonization (e.g., FH-binding peptides) [reviewed in (Ricklin and Lambris, 2016b)]. New
insights into the unique surface selectivity of this new class of C3-targeted inhibitors and the
therapeutic prospects emerging from their preclinical evaluation are discussed below.
3. Therapeutic intervention at the level of C3

Author Manuscript

Positioned at the intersection of all complement activation pathways, C3 is a highly
attractive target for developing complement therapeutics with broad inhibitory potency. All
initiation routes, regardless of their trigger, lead to the formation of C3 convertases that
cleave native C3 into C3b and C3a (Ricklin et al., 2010) (Figure 1). C3a is generally
considered a potent proinflammatory mediator that can activate a multitude of myeloid or
non-myeloid cells through binding to its G-protein-coupled C3aR receptor. Conversely,
recent evidence has suggested that this C3-derived peptide may also exert anti-inflammatory
activity in certain pathophysiological contexts (Wu et al., 2013; Coulthard and Woodruff,
2015). Meanwhile, the C3b opsonin rapidly decorates surfaces undergoing complement
attack and forms the initial component of the AP C3 convertase (C3bBb). Increased C3b
deposition via the CP, or the AP amplification loop is both a prerequisite for the generation
of C5 convertases, which cleave C5 into C5b and the proinflammatory mediator C5a, and
also a common denominator exacerbating the clinical course of several complement-driven
pathologies. Irrespective of the initial route of activation, AP amplification and aberrant C3b
deposition on host surfaces or biomaterials have been implicated as a pivotal pathogenic
driver fueling the tissue-destructive, vicious cycle of inflammation in several conditions
(Ricklin and Lambris, 2013a). Notably, the presence of a contingent of fluid-phase or
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surface-bound C3 regulators that can dismantle C3 convertases or promote the factor I (FI)dependent degradation of C3b ensures the containment of complement responses on host
surfaces. Nevertheless, subtle genetic or functional alterations can tilt the balance between
C3 activation and C3b degradation toward a cell-injurious phenotype that ultimately
exacerbates the course of the disease (Ricklin and Lambris, 2016a).

Author Manuscript

C3 is a large and abundant plasma protein that undergoes a series of conformational
transitions during its activation, releasing bioactive fragments that engage in numerous
protein-protein interactions (Gros et al., 2008). Its dynamic conformational rearrangement
exposes large surfaces for binding and modulation of its activity by biologics or small
molecules that may act as protein-protein interaction (PPI) inhibitors. To date, several
approaches have yielded both larger biologics and also small-molecule inhibitors of C3
activation, which act on native C3 itself, on the C3 convertase, or on the C3b breakdown
cycle (Ricklin and Lambris, 2016a). Targeting native C3 with therapeutic antibodies remains
challenging, but significant progress toward clinical translation has been made with smallsized peptidic inhibitors directly binding to native C3 (Mastellos et al., 2015). While earlier
analogs of these C3-binding peptides have entered clinical development for different
indications, a new series of these C3-targeted inhibitors has emerged with increased potency,
favorable pharmacokinetic profiles, and sustained therapeutic efficacy in primate models that
make them promising candidates for clinical intervention.
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Despite the context- and disease-specific contribution of each complement pathway (i.e.,
upstream or downstream of C3), C3 interception appears to be a more comprehensive
strategy for blocking complement activation because it also abrogates the pathological
consequences of aberrant AP amplification and terminal pathway activation (i.e., MACmediated cytolysis and C5a-triggered responses). It is increasingly recognized that C3targeted therapeutics hold promise for the treatment of disorders largely fueled by AP
amplification and uncontrollable C3 deposition on host surfaces, such as C3
glomerulopathies (C3G) (Smith et al., 2007), and for disorders with broader complement
involvement, such as AMD (Schramm et al., 2014). Furthermore, C3 inhibitors offer
alternative therapeutic avenues that might confer even greater clinical benefit for patients
who are already receiving standard anti-complement therapy, as in the case of individuals
with PNH.

3.1. Aiming at the core: C3-targeted peptidic inhibitors—In contrast to developing
therapeutic antibodies that bind C5 to inhibit its convertase-dependent activation (e.g.,
eculizumab), developing C3 therapeutics that act directly on native C3 to block its cleavage
by C3 convertases has proven quite a challenging trail. To date, the only class of C3
inhibitors that binds directly to native C3, showing sustained inhibitory potency in
preclinical models and potential for complement modulation in a number of clinical
indications, is the compstatin family of peptidic C3 inhibitors (Ricklin and Lambris,
2008;Mastellos et al., 2015). Indeed, both early and next-generation compstatin analogs are
now advancing through clinical development for indications ranging from dry AMD and
PNH to ABO-incompatible kidney transplantation, periodontal disease, and C3G (Ricklin
and Lambris, 2015).
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Compstatin was discovered through a phage-display library screening as a 13-residue cyclic
peptide that selectively binds to native C3 and its bioactive fragments C3b/iC3b/C3c (Sahu
et al., 1996). This C3-binding peptide exerts its broad and potent inhibitory function by
blocking C3 activation by all convertases, thus preventing C3b-opsonization and blunting
essentially all initiation, amplification, and downstream effector responses (Sahu et al.,
2000;Ricklin and Lambris, 2008). Resolution of a co-crystal structure between an early
compstatin analog and human C3c (Janssen et al., 2007) revealed important structural
features that have guided subsequent optimization efforts and propelled our understanding of
its unique binding and inhibitory mode on C3. By binding to a shallow pocket in the !-chain
of C3, compstatin acts as a PPI inhibitor, sterically hindering the binding and cleavage of
native C3 by C3 convertases (Janssen et al., 2007;Ricklin and Lambris, 2008). However, it is
important to note that compstatin and its latest analogs neither prevent the direct cleavage of
C3 by coagulation proteases nor the spontaneous hydrolysis of C3 into C3(H2O) (i.e., C3
“tick-over”). Moreover, C4b opsonization via CP/LP activation remains intact in the
presence of compstatin (Mastellos et al., 2015).
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Resolution of the structure of compstatin in its bound conformation has facilitated rigorous
structure-function optimization of the parental peptide, resulting in improved compstatin
derivatives with enhanced inhibitory potency, prolonged plasma stability, and target binding
affinity almost 6000-fold greater than the original peptide (reviewed in (Qu et al.,
2009;Ricklin and Lambris, 2008;Mastellos et al., 2015)). A combination of enthalpy-driven
peptide modifications (i.e. backbone N-methylation) that approximated the C3-bound
structure of compstatin and increased hydrophobic interactions with the binding pocket in
C3, along with C-terminal substitutions and a structure-guided extension of the N-terminus
with non-proteinogenic amino acids (e.g., D-Tyr) likely affording additional contacts with
C3, have led to a remarkable increase in compstatin's inhibitory potency and binding affinity
(Qu et al., 2013). Collectively, these peptide modifications built the basis for the
development of the potent derivatives Cp20 and Cp40, which exhibit low or sub-nanomolar
affinity for C3, and the Cp40-based therapeutic AMY-101, which is currently under clinical
development by Amyndas Pharmaceuticals (Mastellos et al., 2015).
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Early in the preclinical development phase, it became evident that compstatin-based
inhibitors exhibit narrow species specificity, binding exclusively to human and non-human
primate (NHP) C3 (Sahu et al., 2003). This specificity for primate C3 was largely explained
when the structure of the binding site of compstatin on human C3 was released (Janssen et
al., 2007). While critical residues of the MG4 and MG5 domains of the !-chain, which
mediate the interaction with compstatin, remain conserved in human and primate C3, these
exact residues vary in other mammalian species (Janssen et al, 2007), predicting subtle
structural perturbations that likely obstruct the access of compstatin to its binding site on C3
molecules of non-primate origin.
A first milestone in compstatin's preclinical development was reached by the 4(1MeW)
analog, which displayed sustained inhibitory potency and therapeutic efficacy in NHP
models of systemic inflammatory response syndrome (bacterial sepsis) (Silasi-Mansat et al.,
2010)) and early-onset AMD (Chi et al., 2010). These studies underscored the clinical
potential of this analog, propelling the clinical evaluation of a 4(1MeW)-based candidate
Immunobiology. Author manuscript; available in PMC 2017 October 01.
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(POT-4; Potentia Pharmaceuticals, now Apellis) as a therapeutic option for local (i.e.,
intravitreal) C3 interception in AMD in phase I and II trials (Alcon Research, 2013). In the
meantime, different formulations of the same analog (APL-1 and its PEGylated derivative,
APL-2) are being clinically developed by Apellis for both local and systemic applications
ranging from AMD and PNH to COPD and asthma.
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As opposed to the prolonged efficacy afforded by local application of compstatin analogs in
AMD or periodontitis (discussed below), systemic administration of peptidic C3 inhibitors
presents challenges with regard to pharmacokinetics and plasma stability. In this regard,
extended pharmacokinetic analysis of next-generation compstatin analogs (e.g., Cp40) in
NHP models has revealed a target-driven, biphasic plasma elimination profile that is marked
by a rapid initial clearance, followed by a slower second phase of elimination that is largely
mediated by tight binding of compstatin to plasma C3 (Qu et al., 2013). Whereas compstatin
analogs with binding affinity in the sub-nanomolar range (i.e, Cp40) already show good
pharmacokinetic profiles (Qu et al., 2013), making these agents suitable for sustained
therapeutic intervention, elegant approaches have led to a further increase in plasma
residence. These strategies include PEGylation approaches that have led to an impressive
increase in Cp40's half-life (Risitano et al., 2014), or conjugation of Cp20 to plasma carrier
proteins by means of small albumin-binding tags (Huang et al., 2014). Notably, one of the
albumin-binding compstatin derivatives (ABM2-Cp20) displays a 20-fold higher binding
affinity for C3 (KD = 150 pM) than does the parental peptide, making it the most potent
compstatin analog to date (Huang et al., 2014).
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Their beneficial pharmacokinetic properties and suitability for subcutaneous administration
make Cp40 and other next-generation analogs promising candidate drugs for C3 intervention
in both acute and chronic indications driven by C3 dysregulation and derailed AP
amplification (e.g., hemodialysis, PNH, C3G). AMY-101 (Amyndas), a C3-targeted
therapeutic based on Cp40, shows a significant (6,000-fold) improvement in binding affinity
to human C3 when compared to the original compstatin, as well as an enhanced inhibitory
potency and extended in vivo half-life in NHP when compared to the much shorter half-lives
of earlier compstatin analogs.
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Overall, compstatin's structure-guided optimization has led to an impressive lineup of C3
therapeutics that display favorable pharmacokinetic profiles and sustained biological
efficacy in a wide spectrum of indications. The therapeutic potential and medical plausibility
of targeting native C3 with inhibitors of the compstatin family has recently been endorsed by
international regulatory authorities. First-generation compstatin analogs (Potentia/Apellis)
have received orphan status for PNH from the US Food and Drug Administration (FDA).
Furthermore, a C3-targeted therapeutic based on next-generation compstatin analogs (i.e.,
AMY-101, Amyndas) has received orphan designation from both the European Medicines
Agency (EMA) and the FDA for the treatment of PNH and C3G, two rare diseases
etiologically linked to complement AP dysregulation [reviewed in (Ricklin and Lambris,
2015;Mastellos et al., 2015).
3.2. ”Pinning” the endogenous C3 regulators down to the surface—Exploiting
the body's own homeostatic circuitry of fluid-phase and surface-bound C3 regulators in
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order to modulate complement activation on diseased surfaces has illuminated new
therapeutic directions in the complement field. Several groups have developed C3
therapeutics adopting the “opsonin-targeted” approach that essentially localizes potent
complement inhibitors or regulators to sites of high opsonic turnover via specific molecular
tethers (Holers et al., 2013;Ricklin and Lambris, 2016a). Given that C3 dysregulation is
emerging as a key driver of pathophysiology in a number of inflammatory conditions, the
surface-tethering of potent C3 convertase regulators, such as factor H (FH), and the
engineering of fusion or miniaturized proteins encompassing inhibitory and surfacerecognition modules of C3 regulators have led to attractive therapeutic leads in several APmediated disease models.

Author Manuscript
Author Manuscript

FH-CR2 fusion proteins: The opsonin-targeted approach has provided important proof-ofconcept for the therapeutic potential of targeting complement modulation to diseased
(opsonized) surfaces. An illustrative and pioneering example has been the design of fusion
proteins (e.g., TT30, Taligen; later developed by Alexion) encompassing the regulatory
modules of the AP regulator FH (CCP domains 1-5), combined with the iC3b/C3dg-binding
domains of complement receptor 2 (CR2; CCP1-4) (Fridkis-Hareli et al., 2011). Such
chimeric regulators localize complement modulation to the C3-opsonized surface via their
CR2 tether. In this regard, TT30 has shown therapeutic efficacy in AP-driven disease models
(Banda et al., 2009;Holers et al., 2013) and has been clinically developed for the treatment
of PNH. Whereas a Phase I trial of TT30 has proved successful in untreated PNH patients,
further clinical development of this inhibitor has not yet been reported (Risitano et al.,
2015). Interestingly, this therapeutic concept of opsonin targeting has been extended to other
regulators such as CR1 (i.e., TT32) and has also inspired a diversified spectrum of chimeric
inhibitors/regulators (e.g., FH-MAP1, FH-CRIg, and CD59-CRIg [reviewed in (Ricklin and
Lambris, 2016b)]).
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Mini-FH variants: Key structural insights concerning C3 convertase regulation have been
integrated into a series of miniaturized versions of human FH (mini-FH) with emerging
clinical potential (Schmidt et al., 2013;Hebecker et al., 2013). Despite a significant reduction
in size as compared to FH, these mini-FH molecules have retained the complement
regulatory and surface-recognition capacity of the parental FH by directly combining CCP
domains 1-4 and 19-20 respectively. Mini-FH exhibits an increased AP-targeted inhibitory
potency, binding C3-derived opsonic fragments (iC3b/C3dg) with a higher affinity than that
of FH. This new class of surface-targeted inhibitors (e.g., AMY-201, Amyndas) has shown
promising therapeutic results in an AP-driven disease model, protecting the erythrocytes of
PNH patients from C3 opsonization and intravascular hemolysis (Schmidt et al., 2013).
Notably, a recent study guided by molecular design has revealed distinct selectivity criteria
that determine the relative inhibitory potency of surface-targeted C3 inhibitors on different
C3-opsonized surfaces (Schmidt et al., 2016). In this context, mini-FH showed greater
efficacy in abrogating complement activation on PNH erythrocytes, whereas other targeted
regulator constructs showed distinct activities on different surfaces (Schmidt et al., 2016).
These findings may better guide C3 therapeutic design by allowing us to tailor the
application of surface-targeted inhibitors to appropriate pathologies.
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Recruitment of FH to non-self surfaces: Once a biomaterial surface or xenogeneic tissue
comes into contact with blood, it becomes exposed to complement-mediated opsonization
and an ensuing thromboinflammatory response (Ekdahl et al., 2015). An evolutionarily
conserved mechanism by which microbes evade complement attack is the decoration of their
surface with proteins that can sequester FH from the host's circulation. This primordial
immune evasion strategy has prompted the design of novel therapeutics that exploit targeting
moieties such as peptides for recruiting fluid-phase C3 regulators to non-self or artificial
surfaces (Ricklin and Lambris, 2016a). Recruitment of FH to cells or biomaterial surfaces
coated with an FH-binding peptide (e.g., 5C6) has been shown to prevent AP-driven
complement activation, attenuating blood-mediated thromboinflammatory reactions (Wu et
al., 2011). Such C3 regulator-targeting moieties provide a new therapeutic handle for
containing inflammatory complications in transplantation medicine or biomaterial-triggered
pathologies (Ekdahl et al., 2015;Kourtzelis et al., 2015).
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4. Clinical advancement of compstatin-based C3 inhibitors: State-of-the-art
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As the list of clinical disorders etiologically linked to complement dysregulation grows
longer, it is increasingly appreciated that complement modulation at the level of C3 may
offer broad therapeutic benefit and, in some cases, even superior treatment options to
patients failing to respond to standard anti-complement therapy. Clinical conditions that
present an opportunity for C3-targeted intervention can be classified into acute (or transient)
indications that may benefit from short-term or intermittent C3 interception and chronic
indications that require long-term complement modulation. On their way to clinical
translation, the most potent compstatin derivatives have shown promise as novel therapeutics
in primate models of sepsis-related (Silasi-Mansat et al., 2010) and hemodialysis (HD)induced inflammation (Reis et al., 2014) and in ex vivo models of xenotranslantation
(Kourtzelis et al., 2014), and xenoantibody-mediated toxicity (Wang et al., 2016); they have
also shown profound efficacy in models of AP-driven chronic debilitating diseases such as
PNH and C3G (Risitano et al., 2014;Zhang et al., 2015). Notably, local application of the
current lead analog, Cp40, has recently been shown to attenuate both inducible and naturally
occurring periodontitis in NHP (Maekawa et al., 2014;Maekawa et al., 2016), opening up
new prospects for C3-targeted clinical intervention in this prevalent dysbiotic oral
inflammatory disease. While the application of compstatin analogs in NHP models has
underscored the feasibility of therapeutic intervention at the level of C3 and provided
important insights into disease pathogenesis, it will still be necessary to gain solid clinical
experience by monitoring these C3-targeted therapeutics in future clinical trials.
4.1. Acute indications
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Hemodialysis-induced thromboinflammation: Exposure of biomaterial surfaces (e.g.,
implants, HD filters, or extracorporeal perfusion circuits) to whole blood constituents can
rapidly trigger complement activation that will, in turn, fuel an vicious cycle of
inflammation, leading to procoagulant responses that have detrimental consequences for
organ function (Ekdahl et al., 2015). Recent advances in surface nanopatterning and
biopolymer technology have attempted to bridge the gap of incompatibility in such systems,
but nevertheless, clinical complications remain, largely as the result of recurring biomaterialinduced inflammatory episodes that exacerbate chronic underlying pathologies (Teramura et
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al., 2015). Hemodialysis has been associated with such thromboinflammatory responses,
which likely increase the burden of disease (e.g., risk of cardiovascular disease). Patients
suffering from end-stage renal disease (ESRD) are often forced to rely for many years on
periodic sessions of hemodialysis (HD) because of their deterioration of kidney function and
the shortage of donor replacement organs (Santoro et al., 2013). Interestingly, studies have
shown that even modern “biocompatible” HD filters can trigger appreciable levels of
complement activation and also induce TF expression, thereby contributing to a
thromboinflammatory milieu that can increase morbidity in ESRD patients (Kourtzelis et al.,
2010). Notably, this thromboinflammatory reaction has been shown to be attenuated ex vivo
by the earlier compstatin analog 4(1MeW) (Kourtzelis et al., 2010). Recently, these findings
were recapitulated in a refined, clinically relevant NHP model of HD-induced inflammation
(Reis et al., 2014). Cynomolgus monkeys were subjected to HD using a circuit of pediatric
hemodialysis filters, and significant complement activation was observed even after a single
HD session. Of particular note, a single intravenous bolus injection of compstatin Cp40 prior
to HD completely abrogated HD-induced complement activation and elevated levels of the
anti-inflammatory cytokine IL-10 (Reis et al., 2014). The time-restricted dosing scheme of
Cp40 in hemodialysis allows for rapid recovery of complement activity between sessions,
thereby pointing to a safe and affordable treatment option that may alleviate inflammatory
complications in ESRD patients. Furthermore, the availability of surface-targeting moieties
and coating strategies that can direct soluble C3 regulators to surfaces (Wu et al., 2011)
offers alternative routes for modulating complement activation and containing inflammatory
responses evoked by HD filters and other medically applied biomaterial surfaces (e.g.,
biomedical implants).
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C3 intervention in transplantation: Transplantation medicine encompasses a vibrant area
of investigation that has recently opened up new opportunities for C3-targeted intervention.
Complement activation is increasingly recognized as a key pathogenic driver in acute
antibody-mediated rejection (AMR) following allogeneic organ transplantation (Sacks and
Zhou, 2012;Stegall et al., 2012), and its role in chronic organ rejection is also under debate.
An initial trigger for this tissue-destructive process is the sensitization of transplant
recipients by donor-specific alloantibodies (i.e., HLA and ABO transplantation barriers)
(Biglarnia et al., 2012). Therefore, complement inhibitors targeting either early or late
components of the cascade have gained momentum as potential therapeutic leads for graft
accommodation and long-term survival (Sacks and Zhou, 2012).

Author Manuscript

Therapeutic modulation at the level of C5 has shown promise in alleviating complications of
early AMR and prolonging kidney graft survival. However, a fair proportion of graft
recipients fail to respond to anti-C5 treatment, implying that a broader and more
comprehensive intervention might be warranted (Bentall et al., 2014). In this regard, C3
interception is considered a plausible approach for improving graft accommodation and
function in transplant recipients, given its multifaceted impact on both cell-mediated and
humoral inflammatory pathways. In fact, proof of concept for a role of C3 in promoting
graft accommodation in renal transplantation has been provided in an NHP renal transplant
model employing CVF as a complement-depleting agent (Chen et al., 2011). In addition,
earlier compstatin analogs have shown efficacy in abrogating complement activation and
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cell-mediated inflammation in ex vivo xenotransplantation (xeno-Tx) models (Fiane et al.,
1999;Goto et al., 2008). Indeed, the sustained inhibitory potency and clinical potential of
next-generation compstatin derivatives make them attractive treatment options for
attenuating inflammatory complications in organ transplantation (Mastellos et al., 2015).
Along these lines, the Cp40-based inhibitor AMY-101 (Amyndas Pharmaceuticals) is
currently under clinical development as a therapeutic for improving graft accommodation in
ABO-incompatible kidney transplantation (Mastellos et al., 2015).
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In addition to the transplantation of ABO- or HLA-incompatible organs, xeno-Tx has also
been proposed as a countermeasure to the rapidly escalating shortage of donor organs
(Kourtzelis et al., 2015). However, hyperacute rejection resulting from the instant
thromboinflammatory responses to the xenogeneic tissue is a major hurdle in applying xenoTx in the clinic. Recent studies have highlighted the therapeutic potential of C3-targeted
interception in this emerging clinical field. Indeed, compstatin analogs have shown
promising results, abrogating complement activation and thromboinflammatory cell
activation in a primate model of islet xeno-Tx (Goto et al., 2008), a whole-blood model of
xenogeneic interactions between human blood and porcine endothelium (Kourtzelis et al.,
2014), and in a porcine-to- human model of xenoantibody-induced complement-dependent
cytotoxicity (Wang et al., 2016).
4.2. Chronic indications
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Paroxysmal nocturnal hemoglobinuria (PNH): PNH is a rare hematological disorder
genetically driven by a deficiency of the GPI-anchored proteins CD55 and CD59 on
erythrocytes that leads to chronic AP dysregulation and MAC-mediated intravascular
hemolysis (Takeda et al., 1993;Risitano, 2012). PNH is consistently characterized by three
clinical hallmarks: hemolytic anemia, bone marrow failure, and thrombophilia (Parker et al.,
2005). Given its prominent linkage to complement dysregulation, PNH has long been
considered an ideal paradigm for complement-based therapeutic intervention (Risitano,
2012). The advent of anti-C5 therapy (i.e., eculizumab) has significantly improved the
treatment landscape of PNH (Rother et al., 2007). By abrogating intravascular hemolysis,
this complement-targeted drug has brought clinical benefit to ~70% of PNH patients;
however, a significant fraction of patients receiving anti-C5 are either suboptimal responders
or are refractory to therapy because of complement-related genetic variance and still require
blood transfusions to treat their residual anemia (Risitano et al., 2010;Nishimura et al.,
2014). Interestingly, anti-C5 treatment has unmasked a novel pathogenic mechanism that
explains the limited hematologic benefit afforded to certain PNH patients (Risitano et al.,
2009): Persistent C3-mediated opsonization of surviving PNH RBCs coupled to poorly
controlled AP amplification, resulting from the genetic absence of GPI-linked CD55, may
lead to C3-mediated extravascular hemolysis and chronic residual anemia (Risitano et al.,
2009). Recent in vitro studies have corroborated this clinical observation by showing that
C3dg-opsonized RBCs from eculizumab-treated PNH patients are recognized and efficiently
phagocytosed by macrophages (Lin et al., 2015).
C3 interception has therefore emerged as a promising strategy for controlling the entire
spectrum of detrimental consequences evoked by complement dysregulation in PNH
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(Mastellos et al., 2014). In this respect, peptidic C3 inhibitors with pharmacokinetic profiles
amenable to systemic administration are currently being explored. The compstatin analog
Cp40 has shown efficacy in abrogating MAC-mediated hemolysis of PNH erythrocytes and
also in preventing AP-amplified C3 opsonization (Risitano et al., 2014). From a different
standpoint, C3 regulator-based approaches have also illustrated the clinical potential of
targeting AP amplification closer to the C3-opsonized surface of PNH cells (Risitano et al.,
2012;Schmidt et al., 2013). Collectively, these studies indicate that C3 interception may
afford greater therapeutic benefit to PNH patients than that achieved by anti-C5 therapy, by
also mitigating C3-mediated extravascular hemolysis (Mastellos et al., 2014). The favorable
pharmacokinetic and safety profiles and the sustained efficacy of Cp40/AMY-101 in NHP
models attest to the feasibility of chronic administration of C3 inhibitors in PNH patients. Of
note, the projected annual costs of the standard anti-C5 therapy impose a considerable
economic burden on the healthcare system, likely limiting broader access of patients to this
effective treatment option, particularly in developing countries. Small-sized therapeutics
such as compstatin analogs may present one potential avenue towards more affordable PNH
therapies. Moreover, a different mode of complement inhibition at the level of C3, which can
effectively contain both intravascular and extravascular hemolysis, may potentially result in
broader clinical efficacy in at least the subgroup of PNH patients that show insufficient
response to established treatment. Future clinical trials to validate this new therapeutic
option in PNH patients are highly anticipated.
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Periodontal disease: Periodontitis is a chronic oral inflammatory disease that culminates in
the destruction of the tooth-supporting connective and bone tissue (Hajishengallis, 2014a).
Inflammation induced and perpetuated by dysbiotic bacterial communities in subgingival
tooth sites is the main pathogenic driver of the disease. Chronic periodontitis affects >47%
of U.S. adults (Eke et al., 2012), and its most severe form is associated with increased risk
for certain systemic disorders (e.g., atherosclerosis, diabetes, rheumatoid arthritis, and
adverse pregnancy outcomes) (Hajishengallis, 2015). The serious public health impact of
periodontitis and its economic burden (Beikler and Flemmig, 2011;Chapple, 2014) require
effective and affordable therapeutic options capable of improving on existing therapies
(mechanical removal of the tooth-associated biofilm and antimicrobial treatment), which are
often insufficient to control periodontitis (Colombo et al., 2012;Armitage, 2002;Rams et al.,
2014).
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Recent studies have provided compelling evidence that local complement activation, in
synergy with TLRs, promotes dysbiosis while exacerbating the resulting inflammation and
bone loss in periodontitis [reviewed in (Hajishengallis et al., 2016)]. Indeed, genetic and
pharmacological studies have shown that both C3 and C5aR1 are targets for therapeutic
intervention in models of periodontal disease (Abe et al., 2012;Maekawa et al., 2014). In
view of the broader therapeutic benefit afforded by upstream C3 targeting in many disease
models, the peptidic C3 inhibitor Cp40 has been evaluated as a therapeutic option in an NHP
model of ligature-induced periodontitis. Intragingival treatment of affected monkeys with
Cp40 resulted in attenuation of periodontal inflammation (as evidenced by decreased clinical
indices that measure periodontal inflammation and tissue destruction) and protection from
bone loss over a 6-week period (Maekawa et al., 2014). These protective effects were
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correlated with lower levels of inflammatory and bone resorptive mediators (e.g., TNF,
IL-1!, IL-17) in gingival crevicular fluid and decreased osteoclastogenesis (e.g., RANKL
expression) in bone biopsies. Extending these observations to a more clinically relevant
context, Maekawa and colleagues recently showed that local administration of Cp40 can
effectively reverse the signs of periodontitis (gingival inflammation and osteoclastogenesis)
in an NHP model of chronic, naturally-occurring periodontitis (Maekawa et al., 2016).
Notably, even a single weekly injection of Cp40 for 6 weeks caused a marked reduction in a
panel of clinical indices and laboratory tests reflecting periodontal inflammation and bone
resorption. This protective effect could be maintained for a prolonged period after
discontinuation of therapy (6 weeks), likely indicating long-term effects of C3 inhibition.
Taken together, these findings underscore the clinical potential of Cp40-based therapeutics,
such as AMY-101, in dysbiotic oral inflammation and pave the way for C3-based
immunomodulatory therapies for the treatment of human periodontitis.
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Important questions that remain to be addressed include the most suitable and effective
formulation and dosing scheme and the optimal therapeutic window to prevent or treat
periodontal inflammation and bone loss.
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C3 glomerulopathy: C3 glomerulopathy (C3G) is a recently adopted term that collectively
defines a group of ultra-rare renal disorders characterized by pronounced C3 deposition in
the renal tissue (i.e., glomeruli), in the absence (or scarce presence) of deposited
immunoglobulins (Pickering et al., 2013). C3G is subdivided into two pathological entities:
dense deposit disease (DDD), which encompasses renal pathologies characterized by highly
electron-dense deposits, and C3 glomerulonephritis (C3GN) which describes glomerular
lesions with pronounced C3 deposition, but lacking the characteristic highly electron-dense
transformation (Pickering et al., 2013;Sethi and Fervenza, 2014). Half of all C3G patients
progress to end-stage renal failure within 10 years of diagnosis, and allograft rejection
occurs following kidney transplantation secondary to disease relapse in more than 50% of
transplant recipients. Pathology in C3G patients is largely driven by genetic or acquired AP
dysregulation (Pickering et al., 2013;Servais et al., 2012). Genetic factors predisposing to
C3G include mutations in a wide spectrum of genes encoding AP components and regulators
(e.g., C3, FH, FI, FB) (Servais et al., 2012). The complexity of the genetic landscape
underlying complement dysregulation in C3G is underscored by recently reported
chromosomal aberrations in the complement FH–related (CFHR) gene cluster yielding
CFHR fusion proteins that might deregulate C3 convertase activity (Chen et al., 2014).
Interestingly, a founder mutation in the CFHR5 gene that segregates with families of Cypriot
origin has also been implicated with a form of C3G (CFHR5 nephropathy) (Gale et al.,
2010). C3G is also associated with the presence of autoantibodies that function as acquired
drivers of AP dysregulation. These autoantibodies, termed C3 nephritic factors (C3Nefs),
bind to C3 convertases to prevent their FH-mediated decay, thereby prolonging their halflives and leading to chronic AP dysregulation (Xiao et al., 2014).
Currently, there is no treatment available for C3G. Management is mostly palliative and
includes drugs for blood pressure control and immunosuppressive therapy (Xiao X, et al.
2014). Since AP-mediated complement dysregulation is the main pathological driver of
C3G, C3-targeted intervention has emerged as a promising strategy for mitigating
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pathological sequelae in the renal tissue and improving therapeutic outcomes in C3G
patients. Proof-of-concept for the therapeutic potential and safety of C3 intervention in C3G
was recently provided by a study documenting the efficacy of a soluble form of CR1 in a
pediatric DDD patient (Zhang et al., 2013). The favorable pharmacokinetic profiles and
sustained potency of C3 inhibitors of the compstatin family make them attractive and
affordable drug leads for the treatment of C3G. Indeed, Cp40 has shown consistent efficacy
in reverting complement dysregulation in in vitro models of C3G (Zhang et al., 2015). This
C3-targeted inhibitor can suppress complement-mediated hemolysis in the sera of C3G
patients and reverses complement dysregulation caused by patient-derived autoantibodies.
Moreover, treatment with Cp40 prevents complement dysregulation associated with C3Gpredisposing genetic mutations, suggesting a wider therapeutic impact in both acquired and
genetically driven C3G. These findings not only pave the way for a targeted, disease-specific
therapy for C3G but also open up new prospects for a broad spectrum of C3 therapeutics that
can modulate AP activity, both in the fluid phase and closer to the opsonized surface.
Endorsing the clinical potential of C3-targeted inhibitors, both the EMA and FDA have
accorded the C3 therapeutic AMY-101 an orphan designation for the treatment of C3G
(AMYNDAS Pharmaceuticals, 2016). Notably, AMY-101 is the first complement-targeted
drug to receive orphan designation for this indication.
5. Translational considerations and future outlook
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Translating preclinical findings to the patient's bedside is a multifaceted process that goes
through several clinical and regulatory checkpoints. Furthermore, the projected therapeutic
benefit of any complement-targeted therapy must always be weighed against the potential
risks, and effective mitigation measures should be integrated into the designed protocol.
Along an intensive course of preclinical development, peptidic C3 inhibitors of the
compstatin family have overcome certain concerns often raised with systemic C3
interception and peptide drug development. Such concerns have mostly revolved around
issues of target saturation, plasma stability, feasibility of prolonged complement modulation,
pharmacokinetics, and pathogen immunosurveillance during intervention (Ricklin and
Lambris, 2015). As exemplified by next-generation compstatin analogs, saturable binding to
plasma C3 can be achieved in conjunction with slower plasma elimination rates that are
largely driven by a subnanomolar affinity-binding to C3 (Qu et al., 2013). Moreover, a
highly favourable pharmacokinetic behavior and sustained inhibitory potency have been
observed after subcutaneous (SQ) administration of these C3 inhibitors (Risitano et al.,
2014). This route of administration may offer increased patient compliance in chronic
protocols of C3 intervention that require frequent dosing. Future studies will still have to
explore alternative routes of administration or tailored formulations that may afford greater
therapeutic benefit in a disease-specific context.
With regard to chronic indications, long-term C3 inhibition justifiably stirs discussions about
the maintenance of pathogen immune surveillance. While most of these concerns are
sparked by the increased susceptibility of C3-deficient individuals to infections by
encapsulated bacteria, interpretation can still be rather contextual, as it is not yet clear how
directly these clinical observations might translate to a therapeutic setting using C3
inhibitors. Of note, clinical experience from primary C3 deficiencies indicates that patients
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are more susceptible to opportunistic infections in the earlier stages of life, whereas this
susceptibility later subsides during adulthood, implying the recruitment of compensatory
mechanisms for long-term immunity (Reis et al., 2006). However, given the pivotal role of
various complement proteins (e.g., C3 and C5) in the phagocytic clearance of microbial
intruders, a treatment scheme including vaccination should always be considered alongside
prolonged C3 or C5 inhibitory protocols. Whereas in the clinical practice chronic anti-C5
therapy mandates meningococcal vaccination, additional prophylaxis against highly virulent
encapsulated bacteria, such as pneumococci or Haemophilus influenza, may need to be
considered during prolonged C3 intervention. Acute or transient C3 interception, in
indications such as hemodialysis or transplantation, is not expected to raise any significant
safety concerns, while local application of C3-targeted inhibitors (as in the case of
periodontal diseases) may even prove beneficial for the local containment of bacterial
growth (Hajishengallis et al, 2016), since periodontal dysbiotic microbial communities
thrive on destructive inflammation, which generates nutrients such as collagen peptides and
heme-containing compounds via tissue breakdown (Hajishengallis, 2014b). Of particular
note, anti-C3 treatment with small-sized inhibitors (such as AMY-101/Cp40) can be readily
interrupted in a clinical protocol, allowing for swift recovery of C3 activity during an
infection. Whereas concerns relating to a purportedly increased risk of autoimmune
reactions or immune complex-mediated inflammatory responses during long-term C3
intervention have yet to be validated by concrete evidence (reviewed in (Mastellos et al.,
2015), these issues will have to be carefully monitored during future clinical trials. As with
all clinical protocols that target immunomodulatory systems, safety should always be
reconciled with the projected therapeutic benefit of the treatment in question. In this respect,
the potential safety concerns raised by long-term C3 intervention and their associated riskmitigating measures have been extensively reviewed (Mastellos et al, 2015).
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Undeniably, the complement field is witnessing the assembly of an unprecedented lineup of
therapeutics targeting various steps of the cascade and catering for different clinical
indications. In this respect, C3-targeted therapeutics have gained considerable momentum
through a surge of creative approaches exploiting both fluid-phase and surface-tethered
inhibitors for therapeutic C3 modulation. In light of the emerging evidence that populationwide genetic variance intricately influences patient responses to anti-complement therapy,
future clinical trials will ultimately decide on the translational value of these inhibitors as
stand-alone or adjunct immunotherapeutics for complement-mediated diseases.
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Figure 1.

(Panel A) A simplified schematic overview of the complement cascade with points of
therapeutic intervention by clinically developed C3 inhibitors. Complement activation on
foreign surfaces (e.g. microbial, transplants, biomaterials) or damaged/transformed self
surfaces can be triggered by any of the three pathways (classical, lectin, alternative). All
pathways converge at the cleavage of the central component, C3, by the C3 convertases.
Amplification of the AP is considered a pivotal pathogenic driver in many complementmediated diseases. Activation of C5 by C5 convertases of both the classical and alternative
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pathway leads to the release of the proinflammatory mediator C5a and the assembly of the
cell-perforating MAC (C5b-9). Convertase-independent cleavage of C3 and C5 by
coagulation and fibrinolytic proteases (e.g. plasmin, thrombin) has been implicated as a
bypass pathway of complement activation in certain pathophysiological contexts. C3targeted inhibitors (e.g. Cp40, AMY-101) can provide effective and broad therapeutic
control of the cascade by targeting all pathways at the level of C3 and blocking downstream
complement effector responses (e.g. C5a generation, MAC assembly). Abbreviations: AP,
alternative pathway; MBL, mannose-binding lectin; MASPs, mannose-binding lectin
associated proteases; FP, properdin; FB, factor B; FD factor D; MAC, membrane attack
complex.
(Panel B) Concepts and illustrative examples of C3-targeted therapeutic modulation. Several
inhibitory approaches have been developed and are currently in clinical evaluation as C3targeted therapeutics for various indications. These include: a) systemic or local complement
modulation at the level of C3 (e.g. compstatin analogs), b) surface-targeting of fluid-phase
complement regulators ( e.g. FH) acting at the level of the AP C3 convertase (e.g. mini-FH
variants, CR2-FH fusion constructs:TT30) and c) targeting moieties that recruit endogenous
C3 regulators to the complement-opsonized surface (e.g. FH-binding peptides, 5C6). Blue
arrows indicate ways by which AP C3 convertase activity can be regulated by natural,
chimeric or small-sized C3 inhibitors.
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